[1] 常岑, 张润润, 时一鸣, 等. 中医疗法治疗类风湿性关节炎的研究进展. 中国中药杂志, 2023, 48(2): 329-335. [2] Cramp F. The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue. Rheumatology (Oxford), 2019, 58(5):22-28. [3] Wu CY, Yang HY, Lai JH. Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis. Int J Mol Sci, 2020, 21(11): 4015. [4] Lu H, Yao Y, Yang J, et al. Microbiome-mirna interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities. Rheumatol Int, 2021, 41(9): 1567-1575. [5] Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognosticfactors, and treatment landscape. Clin Exp Rheumatol, 2021, 39(5): 1108-1118. [6] 姜泉. 国际中医临床实践指南 类风湿关节炎(2019-10-11). 世界中医药, 2020, 15(20): 3160-3168. [7] 郭立杰, 王超, 王晓静, 等. 非甾体类抗炎药所致肝损伤的临床病理分析. 药物不良反应杂志, 2020, 22(2): 62-68. [8] 赖荣陶, 陈成伟, 阳文新, 等. 药物性肝损伤因果关系评估量表:RECAM将取代RUCAM?肝脏, 2022, 27(7): 725-729. [9] Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford), 2021, 60(6): 12-20. [10] Costello R, David T, Jani M.Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis. Clin Ther, 2019, 41(7): 1376-1396. [11] Allison R, Guraka A, Shawa IT, et al.Drug induced liver injury - a 2023 update.J Toxicol Environ Health B Crit Rev, 2023,26(8):442-467. [12] Aletaha D, Smolen JS. Does triple conventional synthetic disease-modifying antirheumatic drug therapy improve upon methotrexate as the initial treatment of choice for a rheumatoid arthritis patient? Rheum Dis Clin North Am, 2019, 45(3): 315-324. [13] Qindeel M, Ullah MH, Fakhar-Ud-Din, et al. Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. J Control Release, 2020, 327: 595-615. [14] Gautam S, Tolahunase M, Kumar U, et al. Impact of yoga based mind-body intervention on systemic inflammatory markers and co-morbid depression in active rheumatoid arthritis patients: a randomized controlled trial. Restor Neurol Neurosci, 2019, 37(1): 41-59. [15] Īlgün G, Şahin B. Serial multiple mediation of treatment adherence and disease activity in the relationship between continuity of care and health outcomes among rheumatoid arthritis patients. Int J Health Plann Manage, 2022, 37(6): 3075-3088. [16] Wang F, Tang J, Li Z, et al. Oral methotrexate at doses 15-25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol, 2022, 41(9): 2701-2712. [17] Trouvin AP, Curis E, Nicolis I, et al. Experience of pain is correlated to treatment profile in patients with rheumatoid arthritis, differentiating 5 clusters of patients in a national cohort of 1100 women with rheumatoid arthritis. Joint Bone Spine, 2020, 87(6): 675-676. [18] Ramírez J, Cuervo A, Celis R, et al. Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Rheumatology (Oxford), 2021, 60(2): 667-674. [19] Song D, Zhu X, Wang F, et al. Longitudinal monitor of jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients. Inflammopharmacology, 2021, 29(4): 1131-1138. [20] 陈瑾, 刘传鑫, 杨培, 等. 基于系统药理学的雷公藤配伍甘草治疗类风湿性关节炎作用机制研究. 药物评价研究, 2019, 42(9): 1705-1722. |